knowledge -WSS

knowledge

author：leisure time 2025-10-01 17:34:52 - browse：9143

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Sanofi strikes deal with Novavax, boosting the vaccine maker

WSS

Readout Newsletter: CAR

Amid AI frenzy, a top HHS official's quest to create safeguards

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Telehealth startups turn to complex chronic diseases

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Elevance, private equity launch primary care company

Guidelines to prevent youth baseball injuries need more muscle

Brain worms: The science behind RFK Jr.'s parasitic infection

State Dept. review finds Biden bears some blame for Afghanistan failures

Bird flu outbreak in cows is latest avian flu curveball

State Dept. review finds Biden bears some blame for Afghanistan failures

First U.S. drug developed to treat liver disease MASH is approved

After affirmative action ruling, medical educators look to 'holistic review'

Dairy farmers resist CDC push for PPE against bird flu virus

entertainment

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Bird flu outbreak in cows is latest avian flu curveball

Study: AI not yet building 'n

After gene therapy, two congenitally deaf children hear for the first time

Brain worms: The science behind RFK Jr.'s parasitic infection

First U.S. drug developed to treat liver disease MASH is approved

hotspot

focus

hotspot

explore